Related Experiment Videos
Triggering of peritoneal macrophages with IFN-alpha/beta attenuates the expression of inducible nitric oxide synthase
E López-Collazo1, S Hortelano, A Rojas
1Instituto de Bioquímica (Centro Mixto Consejo Superior de Investigaciones Cientificas-Universidad Compluteuse de Madrid), Facultad de Farmacia, Spain.
Journal of Immunology (Baltimore, Md. : 1950)
|March 24, 1998
Summary
Type I interferons (IFN-alpha/beta) inhibit the expression of inducible nitric oxide synthase (iNOS) by impairing iNOS gene transcription. This inhibition involves blocking NF-kappaB activation, a key factor in iNOS gene expression.
Area of Science:
- Immunology
- Molecular Biology
Background:
- Macrophages play a crucial role in immune responses.
- Inducible nitric oxide synthase (iNOS) is a key enzyme in macrophage-mediated immune functions.
- Type I interferons (IFNs) are critical signaling molecules in innate and adaptive immunity.
Purpose of the Study:
- To investigate the inhibitory effect of type I IFNs on iNOS expression in macrophages.
- To elucidate the molecular mechanisms underlying IFN-alpha/beta-mediated inhibition of iNOS transcription.
Main Methods:
- Peritoneal macrophages were stimulated with IFN-gamma and lipopolysaccharide (LPS).
- Inhibition by IFN-alpha/beta was assessed during early activation.
- Transcriptional activity was evaluated using run-on assays and promoter transfection.
- Activation of transcription factors, including NF-kappaB and IRF-1, was analyzed.
Main Results:
- IFN-alpha/beta significantly inhibited IFN-gamma/LPS-induced iNOS expression.
- IFN-alpha/beta suppressed iNOS gene transcription and promoter activity.
- Inhibition of NF-kappaB activation and IkappaB degradation was observed.
- IFN regulatory factor 1 activity remained unaffected by IFN-alpha/beta.
Conclusions:
- Type I IFNs impair iNOS promoter activity, leading to reduced nitric oxide synthase expression.
- The mechanism involves the inhibition of NF-kappaB signaling pathway.
- This finding has implications for understanding immune regulation in pathophysiological conditions involving type I IFNs.